Bond Indices definition

Bond Indices means any of the iBoxx HY or IG indices (additional information in respect of which is available at www.markit.com). iBoxx cash bond indices are designed to replicate investible investment grade and high yield fixed income markets. By way of example, the Markit iBoxx EUR Liquid High Yield Index is designed to reflect the performance of EUR denominated high yield corporate debt. It consists of EUR denominated high yield bonds issued by both Eurozone and non-Eurozone corporate issuers. In order to be included in the index, the bonds must have an average credit rating of sub-investment grade as determined by Markit iBoxx EUR Investment Grade index (which is made up of consolidated ratings from Fitch Ratings, Moody’s Investor Service, and/or Standard & Poor’s Rating Services). Distressed and defaulted bonds are excluded from this index. Fixed and floating rate bonds are eligible for inclusion in this index. Eligible bonds must have an outstanding face value greater than or equal to EUR 250 million and a minimum time to maturity of two years to be included in this index. Bonds already included in this index are not subject to a minimum time to maturity. Rebalancing of this index occurs once a month at each calendar month-end. The index is market-value weighted with an individual issuer cap of 3% and a country weight cap of 20%. Bond composition and a full description of the index is available at www.markit.com and the above summary of the Markit iBoxx EUR Liquid High Yield Index has been prepared from information obtained from the provider of the mentioned index.
Sample 1Sample 2Sample 3
Bond Indices means any of the iBoxx HY or IG indices (additional information in respect of which is
Sample 1

Examples of Bond Indices in a sentence

  • Individual country or currency exposures typically will not exceed at purchase: Quality and Marketability: Fixed income securities and cash in the portfolio shall have a weighted average rating of A- or better according to the methodology used by the Barclays Capital Global Bond Indices.

  • Hedging positions may be long or short and may take the form of cash, CDS, TRS on Bond Indices, ETFs and options thereon and options on CDS Indices and Equity Indices subject to the conditions set forth in Applicable Laws.

  • The data we use are total returns on Merrill Lynch Government Bond Indices for the US, Germany, and Japan, which are available through Datastream.

  • BIST-KYD CPI Indexed Government Bond Indices are created to reflect the returns of CPI Indexed GDS issued in Turkish Lira (excluding special category state domestic borrowing notes) and traded in DSM as a whole.

  • Such methods include drying while covering with the cloth of any colour, use of solar dryer and other methods.

  • BIST-KYD Corporate Bond Indices are created to reflect the returns of corporate bonds issued through a public offering or sold to qualified investors in Turkish Lira and traded in DSM.

  • BIST-KYD CPI Indexed Government Bond Indices have two different versions with T+0 and T+1 value date prices, the codes and the names of the indices are stated in Article 2.10.

  • Individual country or currency exposures typically will not exceed at purchase: Quality and Marketability: Fixed income securities and cash in the portfolio shall have a weighted average rating of A‐ or better according to the methodology used by the Barclays Capital Global Bond Indices.

  • Special Opportunities Asset Class The Special Opportunities Asset Class will take exposure to developed market structured credit instruments, subject to conditions and limitations imposed by Applicable Laws, including, but not limited to, junior debt and ‘equity’ (subordinated) positions in CLO and other ABS, standardised CDS index tranches, credit ETFs and options thereon, TRS on Bond Indices, options on Indices, and exposure to assets or portfolios of assets through CDS.

  • BIST-KYD CPI Indexed Government Bond Indices are created to reflect the returns of CPI Indexed GDS traded in DSM as a whole.

Related to Bond Indices

  • Second Indication means [***].

  • First Indication means the first disease condition for which a particular Licensed Product has been approved by a Regulatory Authority.

  • Monitoring Indicator means a measure of HSP performance that may be monitored against provincial results or provincial targets, but for which no Performance Target is set;

  • Marketing Approval means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country, necessary for the manufacture, use, storage, import, marketing and sale of a Product in such country.

  • Regulatory Approval means any and all approvals (including MAA Approval, and Pricing and Reimbursement Approval, if applicable), licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of a Product in any country or jurisdiction.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Marketing Approval Application or “MAA” means a New Drug Application (or its equivalent), as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any country.

  • land development application means the application for a land development permit on a form provided by [local jurisdiction] along with the supporting documentation required in Section [Y]-10(a).

  • Commercialization Costs means the out-of-pocket costs and expenses incurred by Adapt or its Affiliates directly attributable to, or reasonably allocable to, the Commercialization of a Product. Commercialization Costs for a Product shall include, preparation of promotional, advertising, communication, medical, and educational materials relating to the Product and other Product literature and selling materials, activities directed to marketing of the Product, including purchase of market data, development and conduct of market research, advertising, public relations, public affairs and other communications with Third Parties regarding the Product; development and conduct of sales force training (including materials, programs and travel to and attendance at training programs) for medical representatives responsible for promoting the Product; and development and maintenance of sales bulletins, call reporting and other monitoring/tracking, sales force targeting, validation and alignment programs and documentation.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Phase III Trial means a Clinical Trial of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States.

  • Regulatory Approval Application means any application submitted to an appropriate Regulatory Authority seeking any Regulatory Approval.

  • Integrated Development Plan means a plan formulated and approved as envisaged in Section 25 of the Municipal Systems Act 2000, as amended.

  • Performance Indicator means a measure of HSP performance for which a Performance Target is set; technical specifications of specific Performance Indicators can be found in the MSAA Indicator Technical Specifications document;

  • Major Market Countries means the United States, Japan, England, Germany, France, Italy and Spain.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Licensed Product means a product or part of a product in the Licensed Field of Use: (A) the making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent; or (B) which is made with, uses or incorporates any Technology.

  • Pivotal Trial means a clinical study in humans of the efficacy and safety of a Licensed Product that is prospectively designed to demonstrate with statistical significance that such product is effective and safe for use in a particular indication in a manner sufficient to file for Marketing Approval of such product and would satisfy the requirements of 21 CFR 312.21(c), or a similar clinical study prescribed by the Regulatory Authorities in a country other than the United States.

  • MAA Approval means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a Product in the Collaborator Territory, but excluding any Pricing and Reimbursement Approval.

  • Economic development project means land and existing or planned improvements suitable for use by an industrial or commercial enterprise, or housing development, or the protection of the environment, including, but not limited to, groundwater or surface water. Economic development project includes necessary buildings, improvements, or structures suitable for and intended for or incidental to use as an industrial or commercial enterprise or housing development; and includes industrial park or industrial site improvements and port improvements or housing development incidental to an industrial or commercial enterprise; and includes the machinery, furnishings, and equipment necessary, suitable, intended for, or incidental to a commercial, industrial, or residential use in connection with the buildings or structures.

  • Direction-indicator lamp means the lamp used to indicate to other road-users that the driver intends to change direction to the right or to the left;

  • Development Application means the development application identified in Item 5 of Schedule 1 and includes all plans, reports models, photomontages, material boards (as amended supplemented) submitted to the consent authority before the determination of that Development Application.

  • Pricing Approval means such governmental approval, agreement, determination or decision establishing prices for a Licensed Product that can be charged and/or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price and/or reimbursement of pharmaceutical products.

  • Regulatory Exclusivity means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a pharmaceutical product other than Patents, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, or pediatric exclusivity.

  • Pivotal Study means (a) a Phase 3 Study that is intended by Celgene to be submitted (together with any other registration trials that are prospectively planned when such Phase 3 Study is initiated) for Regulatory Approval in the U.S. or the EU, or (b) any other clinical study that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which clinical study is a registration trial intended to be sufficient for filing an application for a Regulatory Approval for the Licensed Product in the U.S. or another country or some or all of an extra-national territory, solely as evidenced by the acceptance for filing for a Regulatory Approval for such product after completion of such study.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.